Skip to content
MEI

Search

Search peptides — top sellers first

Shop

GLP-3-RT

Third-party tested

GLP receptor-targeting research peptide, supplied for laboratory study only.

  • Every batch verified by an independent lab, not by us
  • Ships from the US within 1 business day. Stored frozen, and stable at room temperature until you mix it
  • Retest it at any lab. If it doesn't match our report, every dollar back

$99/ 10mg vial

1

VISAAMEXPayPal
Secure checkout

Frequently bought together

Add these to the same order.

BPC-157

BPC-157 · 10mg

Popular · Research

$69
5 Amino 1MQ

5 Amino 1MQ · 50mg

Research

$89
Add all (2)$158

Proof, not promises. Every batch, tested by an outside lab.

Most sellers show one certificate and hope you never ask again. We publish a signed report for every batch we release, tied to the lot number on your vial. Purity is an exact number, not a “passes.” If a batch fails, it never ships.

What happens before a vial reaches you

    GLP-3-RT — molecular specimen
    GLP-1receptor agonist
    GIPreceptor agonist
    Glucagonreceptor agonist

    How GLP-3-RT works

    A triple-incretin research peptide studied for engaging three metabolic receptors at once.

    01

    GLP-1receptor agonist

    Glucagon-like peptide-1 signalling is studied for glucose-dependent insulin release and appetite regulation.

    02

    GIPreceptor agonist

    Glucose-dependent insulinotropic polypeptide is investigated for insulin sensitivity and nutrient handling.

    03

    Glucagonreceptor agonist

    Glucagon-receptor activity is researched for its influence on energy expenditure and hepatic lipid metabolism.

    For research use only. Mechanisms described reflect published research literature.

    What the studies found

    Published findings on this compound, each linked to its source. Animal and lab results are context, not claims about this product.

    Published research on the reference compound class. Provided for scientific context only. Not a claim about the product supplied.

    Weight lossClinical
    −24.2%

    In a 48-week phase 2 trial in adults with obesity, mean body weight fell 24.2% in the highest-dose arm versus 2.1% on placebo, and the reductions scaled with dose.

    vs -2% on placebo
    New England Journal of Medicine 2023 · phase 2 trial

    Reported weight loss scaled with dose across the trial arms.

    Who respondedClinical
    93%

    In the highest-dose arm, 93% of participants lost at least 10% of body weight and 83% lost at least 15%. On placebo those figures were 9% and 2%.

    100% lost 5% or more
    47/50reached a 10% reduction100% reached 5% or more

    Each dot is about 2% of participants in the highest-dose arm; 83% reached at least 15%.

    New England Journal of Medicine 2023 · phase 2 trial
    It kept workingClinical

    Weight loss was larger at week 48 than at week 24 in every dose group — 17.5% at 24 weeks versus 24.2% at 48 weeks in the highest-dose arm.

    12 mg vs placebo
    Highest dosePlacebo

    Relative body weight, baseline = 100. The trial ran to week 48.

    New England Journal of Medicine 2023 · phase 2 trial

    What buyers say

    Common questions

    Quick answers about GLP-3-RT.

    Independently tested, or your money back.

    Test any batch at any lab you like. If it doesn't match our report, you get every dollar back. No return shipping, no forms, no arguments.

    Popular right now